E. D. Martin

发表

Evaluation of graft and recipient risk factors in liver transplantation

M. Senzolo, P. Burra, E. D. Martin, 2009 .

Antiviral treatment for HCV recurrence after liver transplantation: when, how much and for how long?

A. Vitale, M. Senzolo, P. Burra, 2011 .

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

A. Gasbarrini, R. Bruno, G. Filice, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF).

I. Colle, A. Mangia, G. Fattovich, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Real-world data on antiviral treatments for hepatitis C virus infections: Can we deﬁne intention to treat or per protocol analyses?

D. Samuel, C. Robert, O. Lambotte, 2018 .

578 IS THE PRIMARY IMMUNOSUPPRESSIVE DRUG (CYCLOSPORIN A OR TACROLIMUS) PLAYING A ROLE ON THE RESPONSE TO ANTIVIRAL TREATMENT FOR POST-TRANSPLANT HCV RECURRENCE?

F. Ponziani, M. Cescon, M. Senzolo, 2011 .

Influence of Age and Gender Before and After Liver Transplantation

S. Gitto, P. Burra, Patrizia Burra, 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

85 INTERACTION BETWEEN CYCLOSPORINE AND RECIPIENT IL-28B RS12979860 C>T GENETIC POLYMORPHISMS IN THE ACHIEVEMENT OF SUSTAINED VIRAL RESPONSE FOR RECURRENT HEPATITIS C

A. Gasbarrini, F. Ponziani, C. Rigamonti, 2012 .

OC-24 Interaction between cyclosporine and recipient IL-28B rs12979860 C>T genetic polymorphisms in the achievement of sustained viral response for recurrent hepatitis C

A. Gasbarrini, F. Ponziani, C. Rigamonti, 2012 .

Liver injury from cancer immunotherapy using monoclonal immune checkpoint inhibitors

D. Samuel, C. Robert, O. Lambotte, 2018 .

ecipient female gender is a risk factor for graft loss after liver ransplantation for chronic hepatitis C : Evidence from the prospective iver Match cohort uca

M. Rendina, T. Marianelli, E. D. Martin, 2015 .

Treatment and prognosis of acute severe autoimmune hepatitis

M. Rudler, P. Potier, D. Samuel, 2017 .

P0837 : Efficacy of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis

D. Samuel, A. Coilly, D. Vittecoq, 2015 .

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

P. Chanson, J. Soria, D. Samuel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient.

D. Samuel, P. Biondani, E. De Martin, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

P. Chanson, D. Samuel, S. Ederhy, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

A. Gasbarrini, R. Bruno, G. Filice, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The Impact of Hepatitis C and Biliary Complications on Patient and Graft Survival Following Liver Transplantation

E. Verna, P. Gaglio, D. Neri, 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.